My guess is that the Psoriasis trial timeline is being managed to avoid further dilution if possible (as Ph2 is not yet funded). I think they want to finish 1503 ph2 first, then use upfront cash from a 1503 deal to fund Psoriasis Ph2. Whether this works out or not, time will tell. Of course, always the left field possibility of a Permetrex outlicence or 1701 deal to bring some cash in along the way as well.
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-10
-
- There are more pages in this discussion • 171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 35.0¢ | $200.0K | 566.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70286 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 149779 | 6 |
View Market Depth
| Last trade - 10.19am 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
